Advantages and limitations in the assessement of neuroprotective treatment of Parkinson's disease by functional imaging;Contribution et limites de l'imagerie fonctionnelle dans l'évaluation des traitements à visée neuroprotectrice dans la maladie de Parkinson

Revue Neurologique

Volumn 161, Issue 4, 2005, Pages 385-393

  Thobois, S ^a,d   Broussolle, E ^a   Remy, P ^b,c  

^a CERMEP IMAGERIE DU VIVANT   (France)

^b SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d HÔPITAL NEUROLOGIQUE   (France)

Author keywords

Dopamine agonists; Functional imaging; L Dopa; Neuroprotection; Parkinson's disease

Indexed keywords

3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; AROMATIC LEVO AMINO ACID DECARBOXYLASE; DOPA; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PRAMIPEXOLE; RADIOPHARMACEUTICAL AGENT; RTI 32; UNCLASSIFIED DRUG;

CORPUS STRIATUM; DIAGNOSTIC IMAGING; FUNCTIONAL ASSESSMENT; HUMAN; ISOTOPE LABELING; NEUROPROTECTION; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; RADIOISOTOPE DISTRIBUTION; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 17644368515     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0035-3787(05)85068-4     Document Type: Review

References (62)

1. AHLSKOG JE, UITTI RJ, O'CONNOR MK et al. (1999). The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease. MOV Disord, 14: 940-946.
2. AHLSKOG JE. (2003). Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology, 60: 381-389.
3. ASENBAUM S, BRUCKE T, PIRKER W et al. (1997). Imaging of dopamine transporters with iodine-123-beta-CIT and SPECT in Parkinson's disease. J Nucl Med, 38: 1-6.
4. BERNHEIMER H, BIRKMAYER W, HORNYKIEWICZ O, JELLINGER K, SEITELBERGER F. (1973). Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci, 20: 415-455.
5. BERRY MD, JUORIO AV, LI XM, BOULTON AA. (1996). Aromatic L-amino acid decarboxylase: a neglected and misunderstood enzyme. Neurochem Res, 21: 1075-1087.
6. BROOKS DJ. (2003). Imaging end points for monitoring neuroprotection in Parkinson's disease. Ann Neurol, 53 (Suppl 3): S110-S118.
7. BROOKS DJ, FREY KA, MAREK KL et al. (2003). Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Exp Neurol, 184 (Suppl 1): S68-79.
8. BROUSSOLLE E, DENTRESANGLE C, LANDAIS P et al. (1999). The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson's disease. J Neurol Sci, 166: 141-151.
9. CARVEY PM, PIERI S, LING ZD. (1997). Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole. J Neural Transm, 104: 209-228.
10. DE KEYSER J, EBINGER G, VAUQUELIN G. (1990). Age-related changes in the human nigrostriatal dopaminergic system. Ann Neurol, 27: 157-161.
11. DEFER GL, WIDNER H, MARIE RM, REMY P, LEVIVIER M. (1999). Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD). Mov Disord, 14: 572-584.
12. EKESBO A, RYDIN E, TORSTENSON R, SYDOW O, LAENGSTROM B, TEDROFF J. (1999). Dopamine autoreceptor function is lost in advanced Parkinson's disease. Neurology, 52: 120-125.
13. FAHN S, ELTON RL FOR THE UPDRS DEVELOPMENT COMMITTEE. (1987). Unified Parkinson's disease Rating Scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, eds. Recent Development in Parkinson's disease. Vol 2. Florham Park, NJ: Mac Millan Healthcare Information; 153-163.
14. FAHN S, PARKINSON STUDY GROUP. (2002). Results of ELLDOPA (Earlier vs. Later Levodopa) study. Mov Disord, 17 (Suppl 5): S13-S14.
15. FEARNLEY JM, LEES AJ. (1991). Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain, 114: 2283-2301.
16. FIRNAU G, SOOD S, CHIRAKAL R, NAHMIAS C, GARNETT ES. (1987). Cerebral metabolism of 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine in the primate. J Neurochem, 48: 1077-1082.
17. GNANALINGHAM KK, ROBERTSON RG. (1994). The effects of chronic continuous versus intermittent levodopa treatments on striatal and extrastriatal D1 and D2 dopamine receptors and dopamine uptake sites in the 6-hydroxydopamine lesioned rat-an autoradiographic study. Brain Res, 640: 185-194.
18. GUTTMAN M, STEWART D, HUSSEY D, WILSON A, HOULE S, KISH S. (2001). Influence of L-Dopa and pramipexole on striatal dopamine transporter in early PD. Neurology, 56: 1559-1564.
19. HADJICONSTANTINOU M, WEMLINGER TA, SYLVIA CP, HUBBLE JP, NEFF NH. (1993). Aromatic L-amino acid decarboxylase activity of mouse striatum is modulated via dopamine receptors. J Neurochem, 6O: 2175-2180.
20. HALL ED, ANDRUS PK, OOSTVEEN JA, ALTHAUS JS, VONVOIGTLANDER PF. (1996). Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons. Brain Res, 742: 80-88.
21. IIDA M, MIYAZAKI I, TANAKA K, KABUTO H, IWATA-ICHIKAWA E, OGAWA N. (1999). Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res, 838: 51-59.
22. IKAWA K, WATANABE A, KANENO S, TORU M. (1993). Modulation of [3H]mazindol binding sites in rat striatum by dopaminergic agents. Eur J Pharmacol, 250: 261-266.
23. INNIS RB, MAREK KL, SHEFF K, ZOGHBI S, CASTRONUOVO J, FEIGIN A, SEIBYL JP. (1999). Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [1231]beta-CIT. Mov Disord, 14: 436-442.
24. LANGSTON JW, WIDNER H, GOETZ CG, BROOKS D, FAHN S, FREEMAN T, WATTS R. (1992). Core assessment program for intracerebral transplantations (CAPIT). Mov Disord, 7: 2-13.
25. LARUELLE M, WALLACE E, SEIBYL JP et al. (1994). Graphical, kinetic, and equilibrium analyses of in vivo [1231] beta-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab, 14: 982-994.
26. LEE CS, SAMII A, SOSI V et al. (2000). In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol, 47: 493-503.
27. LEVIEL V. (2001). The reverse transport of DA, what physiological significance? Neurochem Int, 38: 83-106.
28. MAREKK, INNIS R, VAN DYCK C et al. (2001). [1231]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology, 57: 2089-2094.
29. MEIERGERD SM, PATTERSON TA, SCHENK JO. (1993). D2 receptors may modulate the function of the striatal transporter for dopamine: kinetic evidence from studies in vitro and in vivo. J Neurochem, 61: 764-767.
30. MELAMED E, GLOBUS M, FRIEDLENDER E, ROSENTHAL J. (1983). Chronic L-Dopa administration decreases striatal accumulation of dopamine from exogenous L-Dopa in rats with intact nigrostriatal projections. Neurology, 33: 950-953.
31. MORRISH PK, RAKSHI JS, BAILEY DL, SAWLE GV, BROOKS DJ. (1998). Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]Dopa PET. J Neurol Neurosurg Psychiatry, 64: 314-319.
32. MORRISH P. (2002). Is it time to abandon functional imaging in the study of neuroprotection? Mov Disord, 17: 229-232.
33. MORRISH P. (2003). How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson's disease? Mov Disord, 18 (Suppl 7): S63-S70.
34. MURER MG, DZIEWCZAPOLSKI G, MENALLED LB, GARCIA MC, AGID Y, GERSHANIK O, RAISMAN-VOZARI R. (1998). Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol, 43: 561-575.
35. NIRENBERG MJ, VAUGHAN RA, UHL GR, KUHAR MJ, PICKEL VM. (1996). The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J Neurosci, 16: 436-447.
36. NISHIBAYASHI S, ASANUMA M, KOHNO M, GOMEZ-VARGAS M, OGAWA N. (1996). Scavenging effects of dopamine agonists on nitric oxide radicals. J Neurochem, 67: 2208-2211.
37. 18F]CFT PET study. J Cereb Blood Flow Metab, 20: 1604-1609.
38. NUTT JG, CARTER JH, LEA ES, SEXTON GJ. (2002). Evolution of the response to levodopa during the first 4 years of therapy. Ann Neurol, 51: 686-693.
39. OGAWA N, TANAKA K, ASANUMA M et al. (1994). Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro. Brain Res, 657: 207-213.
40. OTSUKA M, ICHIYA Y, KUWABARA Y et al. (1996). Differences in the reduced 18F-Dopa uptakes of the caudate and the putamen in Parkinson's disease: correlations with the three main symptoms. J Neurol Sci, 136: 169-173.
41. PARKINSON STUDY GROUP. (1989). DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group. Arch Neurol, 46: 1052-1060.
42. PARKINSON STUDY GROUP. (2002). Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA, 287: 1653-1661.
43. PATE BD, KAWAMATA T, YAMADA T et al. (1993). Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann Neurol, 34: 331-338.
44. PIRKER W, HOLLER I, GERSCHLAGER W, ASENBAUM S, ZETTINIG G, BRUCKE T. (2003). Measuring the rate of progression of Parkinson's disease over a 5-year period with beta-CIT SPECT. Mov Disord, 18: 1266-1272.
45. POYOT T, CONDE F, GREGOIRE MC et al. (2001). Anatomic and biochemical correlates of the dopamine transporter ligand 11C-PE2I in normal and parkinsonian primates: comparison with 6-[18F]fluoro-L-dopa. J Cereb Blood Flow Metab, 21: 782-792.
46. RAKSHI JS, BAILEY DL, MORRISH PK, BROOKS DJ. (1996). Implementation of 3D acquisition, reconstruction, and analysis of dynamic [18F]-fluorodopa studies. In: Myers R, Cunningham V, Bailey D, Jones T, eds. Quantification of brain function using PET. San Diego: Academic Press: 82-87.
47. RASCOL O, BROOKS DJ, KORCZYN AD, DE DEYN PP, CLARKE CE, LANG AE. (2000). A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med, 342: 1484-1491.
48. RIBEIRO MJ, VIDAILHET M, LOC'H C et al. (2002). Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease. Arch Neurol, 59: 580-586.
49. SCHULZER M, MAK E, CALNE DB. (1992). The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic. Ann Neurol, 32: 795-798.
50. SEIBYL JP, MAREK KL, QUINLAN D et al. (1995). Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol, 38: 589-598.
51. SEIBYL JP, MAREK K, SHEFF K et al. (1997). Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients. J Nucl Med, 38: 1453-1459.
52. SNOW BJ, TOOYAMA I, MCGEER EG, YAMADA T, CALNE DB, TAKAHASHI H, KIMURA H. (1993). Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol, 34: 324-330.
53. STOCCHI F, OLANOW CW. (2003). Neuroprotection in Parkinson's disease: clinical trials. Ann Neurol, 53 (Suppl 3): S87-S97.
54. TORSTENSON R, HARTVIG P, LANGSTROM B, WESTERBERG G, TEDROFF J. (1997). Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease. Ann Neurol, 41: 334-340.
55. TURJANSKI N, LEES AJ, BROOKS DJ. (1999). Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies. Neurology, 52: 932-937.
56. VANDER BORGHT T, KILBOURN M, DESMOND T, KUHL D, FREY K. (1995). The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol, 294: 577-583.
57. VINGERHOETS FJG, SCHULZER M, CALNE DB, SNOW BJ. (1997). Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol, 41: 58-64.
58. VOLKOW ND, DING Y-S, FOWLER J et al. (1996). Dopamine transporters decrease with age. J Nucl Med, 37: 554-559.
59. WARD CD. (1994). Does selegiline delay progression of Parkinson's disease? A critical re-evaluation of the DATATOP study. J Neurol Neurosurg Psychiatry, 57: 217-220.
60. WHONE AL, WATTS RL, STOESSL AJ et al. (2003). Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol, 54: 93-101.
61. WINOGRODZKA A, BERGMANS P, BOOIJ J, VAN ROYEN EA, STOOF JC, WOLTERS EC. (2003). [(123)I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease. J Neurol Neurosurg Psychiatry, 74: 294-298.
62. YEE RE, CHENG DW, HUANG SC, NAMAVARI M, SATYAMURTHY N, BARRIO JR. (2001). Blood-brain barrier and neuronal membrane transport of 6-[18F]fluoro-L-DOPA. Biochem Pharmacol, 62. 1409-1415